Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea

European Journal of Haematology

Volumn 93, Issue 5, 2014, Pages 377-383

  Nottage, Kerri A ^a   Ware, Russell E ^b   Winter, Bryan ^a   Smeltzer, Matthew ^a   Wang, Winfred C ^a   Hankins, Jane S ^a   Dertinger, Stephen D ^c   Shulkin, Barry ^a   Aygun, Banu ^d  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c LITRON LABORATORIES   (United States)

^d Northwell Health   (United States)

Author keywords

Hydroxyurea; Sickle cell disease; Splenic function

Indexed keywords

HEMOGLOBIN F; HYDROXYUREA; LACTATE DEHYDROGENASE; TECHNETIUM 99M; ANTISICKLING AGENT; DITHIO-BISPHOSPHINE TC99M; TECHNETIUM COMPLEX;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COHORT ANALYSIS; DRUG DOSE INCREASE; DRUG EFFECT; DRUG UPTAKE; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE; LIVER SCINTISCANNING; MALE; MAXIMUM TOLERATED DOSE; MEAN CORPUSCULAR VOLUME; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; SICKLE CELL ANEMIA; SPLEEN FUNCTION; SPLEEN SCINTISCANNING; THROMBOCYTE; AGE; ANEMIA, SICKLE CELL; DIAGNOSTIC USE; DRUG EFFECTS; LIVER; METABOLISM; PATHOLOGY; PRESCHOOL CHILD; SCINTISCANNING; SPLEEN;

ADOLESCENT; AGE FACTORS; ANEMIA, SICKLE CELL; ANTISICKLING AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FETAL HEMOGLOBIN; HUMANS; HYDROXYUREA; LIVER; MALE; ORGANOTECHNETIUM COMPOUNDS; PROSPECTIVE STUDIES; SPLEEN;

EID: 84911973714     PISSN: 09024441     EISSN: 16000609     Source Type: Journal    
DOI: 10.1111/ejh.12361     Document Type: Article

References (30)

1. Brown AK, Sleeper LA, Miller ST, Pegelow CH, Gill FM, Waclawiw MA. Reference values and hematologic changes from birth to 5 years in patients with sickle cell disease. Cooperative Study of Sickle Cell Disease. Arch Pediatr Adolesc Med 1994;148:796-804.
2. Pearson HA, Gallagher D, Chilcote R, Sullivan E, Wilimas J, Espeland M, Ritchey AK. Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics 1985;76:392-7.
3. John AB, Ramlal A, Jackson H, Maude GH, Sharma AW, Serjeant GR. Prevention of pneumococcal infection in children with homozygous sickle cell disease. Br Med J (Clin Res Ed) 1984;288:1567-70.
4. Adamkiewicz TV, Sarnaik S, Buchanan GR, et al. Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr 2003;143:438-44.
5. Adamkiewicz TV, Silk BJ, Howgate J, Baughman W, Strayhorn G, Sullivan K, Farley MM. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life. Pediatrics 2008;121:562-9.
6. O'Brien KL, Swift AJ, Winkelstein JA, et al. Safety and immunogenicity of heptavalent pneumococcal vaccine conjugated to CRM(197) among infants with sickle cell disease. Pneumococcal Conjugate Vaccine Study Group. Pediatrics 2000;106:965-72.
7. Gaston MH, Verter JI, Woods G, et al. Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. N Engl J Med 1986;314:1593-9.
8. Leikin SL, Gallagher D, Kinney TR, Sloane D, Klug P, Rida W. Mortality in children and adolescents with sickle cell disease. Cooperative Study of Sickle Cell Disease. Pediatrics 1989;84:500-8.
9. Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH. Klug PP. Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 1994;330:1639-44.
10. Charache S, Terrin ML, Moore RD, Dover GJ, Barton FB, Eckert SV, McMahon RP, Bonds DR. Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med 1995;332:1317-22.
11. Kinney TR, Helms RW, O'Branski EE, et al. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood 1999;94:1550-4.
12. Wang WC, Ware RE, Miller ST, et al. Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet 2011;377:1663-72.
13. Nottage KA, Hankins JS, Smeltzer M, Mzayek F, Wang WC, Aygun B, Gurney JG. Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program. PLoS ONE 2013;8:e72077.
14. Steinberg MH, McCarthy WF, Castro O, et al. The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: a 17.5 year follow-up. Am J Hematol 2010;85:403-8.
15. Voskaridou E, Christoulas D, Bilalis A, Plata E, Varvagiannis K, Stamatopoulos G, Sinopoulou K, Balassopoulou A, Loukopoulos D, Terpos E. The effect of prolonged administration of hydroxyurea on morbidity and mortality in adult patients with sickle cell syndromes: results of a 17-year, single-center trial (LaSHS). Blood 2010;115:2354-63.
16. Lobo CL, Pinto JF, Nascimento EM, Moura PG, Cardoso GP, Hankins JS. The effect of hydroxcarbamide therapy on survival of children with sickle cell disease. Br J Haematol 2013;161:852-60.
17. Aygun B, Mortier NA, Smeltzer MP, Hankins JS, Ware RE. Glomerular hyperfiltration and albuminuria in children with sickle cell anemia. Pediatr Nephrol 2011;26:1285-90.
18. Fitzhugh CD, Wigfall DR, Ware RE. Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatr Blood Cancer 2005;45:982-5.
19. Singh SA, Koumbourlis AC, Aygun B. Resolution of chronic hypoxemia in pediatric sickle cell patients after treatment with hydroxyurea. Pediatr Blood Cancer 2008;50:1258-60.
20. Puffer E, Schatz J, Roberts CW. The association of oral hydroxyurea therapy with improved cognitive functioning in sickle cell disease. Child Neuropsychol 2007;13:142-54.
21. Hankins JS, Helton KJ, McCarville MB, Li CS, Wang WC, Ware RE. Preservation of spleen and brain function in children with sickle cell anemia treated with hydroxyurea. Pediatr Blood Cancer 2008;50:293-7.
22. Olivieri NF, Vichinsky EP. Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol 1998;20:26-31.
23. Claster S, Vichinsky E. First report of reversal of organ dysfunction in sickle cell anemia by the use of hydroxyurea: splenic regeneration. Blood 1996;88:1951-3.
24. Heeney MM, Ware RE. Hydroxyurea for children with sickle cell disease. Hematol Oncol Clin North Am 2010;24:199-214.
25. Zimmerman SA, Schultz WH, Davis JS, Pickens CV, Mortier NA, Howard TA, Ware RE. Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood 2004;103:2039-45.
26. Dertinger SD, Miller RK, Brewer K, Smudzin T, Torous DK, Roberts DJ, Avlasevich SL, Bryce SM, Sugunan S, Chen Y. Automated human blood micronucleated reticulocyte measurements for rapid assessment of chromosomal damage. Mutat Res 2007;626:111-9.
27. Santos A, Pinheiro V, Anjos C, Brandalise S, Fahel F, Lima M, Etchebehere E, Ramos C, Camargo EE. Scintigraphic follow-up of the effects of therapy with hydroxyurea on splenic function in patients with sickle cell disease. Eur J Nucl Med Mol Imaging 2002;29:536-41.
28. Ware RE, Despotovic JM, Mortier NA, et al. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. Blood 2011;118:4985-91.
29. Harrod VL, Howard TA, Zimmerman SA, Dertinger SD, Ware RE. Quantitative analysis of Howell-Jolly bodies in children with sickle cell disease. Exp Hematol 2007;35:179-83.
30. McGann PT, Flanagan JM, Howard TA, Dertinger SD, He J, Kulharya AS, Thompson BW, Ware RE. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatr Blood Cancer 2012;59:254-7.